Skip to content

Valneva

  • About Us
    About Us Advancing vaccines for better lives Learn More
    • Our Strategy
    • Our Responsibility
    • Our Team
  • Products
    Products Focusing on vaccines for infectious diseases with high unmet needs. Learn More
    • Japanese Encephalitis Vaccine
    • Cholera Vaccine
    • Marketing and Distribution
    • Manufacturing and Services
  • R&D
    R&D Dedicated to innovation in vaccine research and development. Learn More
    • Pipeline
    • Lyme Disease – VLA15
    • Chikungunya – VLA1553
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
  • Investors
    Investors Unlocking value for our shareholders Learn More
    • Events and Presentations
      • Calendar
      • Corporate Presentations
      • Videos and Webcasts
    • Financial Reports
    • Stock Information
      • Stock Price
      • Analysts
      • Shareholder Structure
      • Vienna Stock Exchange Delisting
    • Corporate Governance
      • Corporate Compliance & Ethics
    • Regulated Information
    • Annual General Meeting
    • Contact
  • Media
    Media Press releases, latest news and media resources Learn More
    • Press Releases
    • In The News
    • Scientific Publications
    • Media Kit
    • Media Contact
  • Careers
Contact
  • EN
  • FR
Search

Documents in Connection with the Cross-Border Merger

Joint merger plan dated December 16, 2012

Amendment to the merger plan dated January 18, 2013­

Pro forma income statement (non-GAAP):

Audited financial statements and status reports as well as corporate governance reports, to the extent that these had to be prepared in accordance with the legal regulations, of Intercell AG for the last three financial years­

  • 2012 Annual Report
  • 2012 Statutory Financial Statements
  • 2011 Annual Report
  • 2011 Statutory Financial Statements
  • 2010 Annual Report
  • 2010 Statutory Financial Statements

Interim financial statements of Intercell AG as of June 30, 2012­

Interim financial statements of Vivalis SA as of June 30, 2012 ­

Merger report of the Management Board of Intercell AG (in German) ­

Merger report of the Management Board of Vivalis SA (in French)­

Audit report of the merger auditor appointed by the Supervisory Board of Intercell AG, Grant Thornton

Audit report of the SE conversion auditor, Grant Thornton appointed upon application of Vivalis SA by the president of the Commercial Court in Angers (in French)

Merger report of the Supervisory Board of Intercell AG

Audit report of Deloitte as auditor of Vivalis SA on the issuance of the Preferred Shares (in French)

Notice merger according to Section 10 para 4 Austrian Capital Markets­

Notice merger pursuant to section 19 of the Act on the Statute for a European Company

Valneva

  • About Us
  • Products
  • R&D
  • Investors
  • Media
  • Careers
Related Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
Contact
© 2019 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Declaration
  • EU-US Privacy Shield Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019